{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:05Z","timestamp":1761663605757},"reference-count":61,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.vaccine.2017.04.029","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T14:31:04Z","timestamp":1493994664000},"page":"3162-3170","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines"],"prefix":"10.1016","volume":"35","author":[{"given":"Kinnera E.","family":"Chada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.029_b0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14712598.2013.748030","article-title":"Aflunov(R): a vaccine tailored for pre-pandemic and pandemic approaches against influenza","volume":"13","author":"Del","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2017.04.029_b0010","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/JVI.02107-10","article-title":"Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets","volume":"85","author":"Khurana","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0015","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1126\/science.1213362","article-title":"Airborne transmission of influenza A\/H5N1 virus between ferrets","volume":"336","author":"Herfst","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2017.04.029_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virusres.2013.07.017","article-title":"Transmission of influenza A\/H5N1 viruses in mammals","volume":"178","author":"Imai","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2017.04.029_b0025","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4161\/hv.6.10.12915","article-title":"Pre-pandemic and pandemic influenza vaccines","volume":"6","author":"Rockman","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2017.04.029_b0030","unstructured":"Aflunov. Prepandemic influenza H5N1 vaccine (surface antigen, inactivated, adjuvanted). Committee for Medicinal Products for Human Use (CHMP). 2011."},{"key":"10.1016\/j.vaccine.2017.04.029_b0035","unstructured":"H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure. GlaxoSmithKline press release. 2013."},{"key":"10.1016\/j.vaccine.2017.04.029_b0040","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1128\/CVI.00373-12","article-title":"Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A\/H5N1 prepandemic influenza vaccine in adult and elderly subjects","volume":"19","author":"Bihari","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0045","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1517\/17425247.5.10.1139","article-title":"Vaccines against epidemic and pandemic influenza","volume":"5","author":"Hoelscher","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2017.04.029_b0050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/14712590903066695","article-title":"Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data","volume":"9","author":"Leroux-Roels","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2017.04.029_b0055","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(08)70232-9","article-title":"Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans","volume":"8","author":"Jennings","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev.med.050908.132031","article-title":"H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic","volume":"61","author":"Sambhara","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.vaccine.2017.04.029_b0065","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.04.029_b0070","unstructured":"Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). Committee for guidance for human medicinal products (CHMP). EMEA\/CPMP\/VEG\/4717\/2003- Rev. 1. 2008."},{"key":"10.1016\/j.vaccine.2017.04.029_b0075","unstructured":"Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Center for Biologics Evaluation and Research (CBER). 2009."},{"key":"10.1016\/j.vaccine.2017.04.029_b0080","unstructured":"Pumarix. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted). Committee for Medicinal Products for Human Use (CHMP). 2011."},{"key":"10.1016\/j.vaccine.2017.04.029_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000624","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.04.029_b0090","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2017.04.029_b0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/erv.09.16","article-title":"Progress with human H5N1 vaccines: a perspective from industry","volume":"8","author":"Palache","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.029_b0100","unstructured":"Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Committee for Guidance for Human Medicinal Products (CHMP).EMEA\/CHMP\/VWP\/263499\/2006. 2007."},{"key":"10.1016\/j.vaccine.2017.04.029_b0105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(09)70153-7","article-title":"Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis","volume":"9","author":"Manzoli","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0110","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/hv.19917","article-title":"Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses","volume":"8","author":"Manzoli","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.029_b0115","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/j.vaccine.2010.03.068","article-title":"Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature","volume":"28","author":"Prieto-Lara","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0120","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.vaccine.2012.11.002","article-title":"Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months","volume":"31","author":"Risi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00063030-200822050-00001","article-title":"Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus","volume":"22","author":"Carter","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2017.04.029_b0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/erv.11.170","article-title":"Aflunov((R)): a prepandemic influenza vaccine","volume":"11","author":"Gasparini","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.029_b0135","unstructured":"Bidwelld S, Jensen MF. Chapter 3: Using a Search Protocol to Identify Sources of Information: the COSI Model. In: I A, LA T, editors. Etext on Health Technology Assessment (HTA) information resources. Bethesda, MD: National Information Center on Health Services Research and Health Care Technology (NICHSR) of the U.S. National Library of Medicine; 2008."},{"key":"10.1016\/j.vaccine.2017.04.029_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.vaccine.2017.04.029_b0145","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.029_b0150","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1016\/j.vaccine.2009.07.102","article-title":"Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults","volume":"27","author":"Chu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0155","first-page":"136","article-title":"A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A\/H5N1 influenza vaccine in adult and elderly subjects","volume":"53","author":"Czajka","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2017.04.029_b0160","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.04.029_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"Gillard","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2017.04.029_b0170","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1086\/652701","article-title":"Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1\/2 trial in adults","volume":"201","author":"Langley","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0175","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0180","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1016\/j.vaccine.2009.01.040","article-title":"Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0185","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jclinepi.2011.10.009","article-title":"Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis","volume":"65","author":"Langan","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0190","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1536867X1201200403","article-title":"Graphical augmentations to the funnel plot to assess the impact of a new study on an existing meta-analysis","volume":"12","author":"Crowther","year":"2012","journal-title":"Stata J."},{"key":"10.1016\/j.vaccine.2017.04.029_b0195","doi-asserted-by":"crossref","first-page":"e1665","DOI":"10.1371\/journal.pone.0001665","article-title":"Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine","volume":"3","author":"Leroux-Roels","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.029_b0200","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/S0149-2918(11)00024-5","article-title":"A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses","volume":"32","author":"Beran","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.vaccine.2017.04.029_b0205","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.vaccine.2011.12.009","article-title":"Safety and immunogenicity of an MF59((R))-adjuvanted A\/H5N1 pre-pandemic influenza vaccine in adults and the elderly","volume":"30","author":"Vesikari","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/infdis\/jir328","article-title":"Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults","volume":"204","author":"Lasko","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/1471-2334-10-338","article-title":"A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults","volume":"10","author":"Nagai","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jfma.2011.02.006","article-title":"Safety and immunogenicity of a split-virion AS03A-adjuvanted A\/Indonesia\/05\/2005 (H5N1) vaccine in Taiwanese adults","volume":"111","author":"Yang","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.vaccine.2017.04.029_b0225","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2015.04.027","article-title":"Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study","volume":"33","author":"Izurieta","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.vaccine.2017.04.029_b0235","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/CVI.00461-09","article-title":"A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly","volume":"17","author":"Fragapane","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0240","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1016\/j.vaccine.2009.07.079","article-title":"Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses","volume":"27","author":"Alberini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0245","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/eji.201242563","article-title":"Impact of preexisting memory to seasonal A\/H1N1 influenza virus on the immune response following vaccination against avian A\/H5N1 virus","volume":"43","author":"Buricchi","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0250","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1086\/428948","article-title":"Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a potential priming strategy","volume":"191","author":"Stephenson","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0255","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.04.029_b0260","doi-asserted-by":"crossref","first-page":"e16650","DOI":"10.1371\/journal.pone.0016650","article-title":"Immunogenicity and cross-reactivity of 2009\u20132010 inactivated seasonal influenza vaccine in US adults and elderly","volume":"6","author":"Xie","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.029_b0265","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1128\/CVI.00062-09","article-title":"Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans","volume":"16","author":"Kitphati","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0270","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.029_b0275","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and Safety of H5N1 A\/Vietnam\/1194\/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.04.029_b0280","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4161\/hv.20248","article-title":"Homologous and heterologous antibody responses to a one-year booster dose of an MF59((R)) adjuvanted A\/H5N1 pre-pandemic influenza vaccine in pediatric subjects","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.04.029_b0285","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.04.029_b0290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2009.10.017","article-title":"Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0295","doi-asserted-by":"crossref","first-page":"e95496","DOI":"10.1371\/journal.pone.0095496","article-title":"Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization","volume":"9","author":"Khurana","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2017.04.029_b0300","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.vaccine.2017.02.057","article-title":"Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial","volume":"35","author":"Madan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.029_b0305","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1016\/j.vaccine.2015.06.053","article-title":"AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes","volume":"33","author":"Mallett","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17305078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T07:44:28Z","timestamp":1658994268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17305078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":61,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0264410X17305078"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}